Interleukin-2 induces chemotactic deficiency in patients with onco hematologic malignancies and autologous bone marrow transplantation. 1991

A M Stoppa, and C Fossat, and D Blaise, and P Viens, and M Brandely, and C N Pourreau, and D Sainty, and G Novakovitch, and M Miquel, and I Juhan-Vague
Department of Haematology, Institut Paoli Calmettes, Marseille, France.

Unusual gram positive bacteremia has been reported in non granulopenic patients receiving recombinant human interleukin-2 (IL-2) suggesting a beneficial effect of anti gram positive prophylaxis in such patients. We report here studies on granulocyte functions examined during the course of high dose IL-2 therapy (16 to 24 million IU/m2/days for 11 to 18 days) administered during a period of 35 days in 14 patients including 4 solid tumors, 5 chronic myeloid leukemias, 4 recipients of autologous bone marrow transplant (ABMT) and 1 recipient of syngeneic bone marrow transplant. Neutrophils functions were studied before IL-2 administration (d 0), after the first cycle (d 8) and after the third cycle (d 36). Nylon fiber adherence, superoxide production, random migration, phagocytosis, nitroblue tetrazolium reduction, lysozyme and elastase release were not impaired significantly throughout therapy. However N-Formyl-Methionyl-Leucyl-Phenylalanine (FMLP) stimulated chemotaxis of granulocytes, normal before therapy, was significantly impaired as early at d 8 and severely inhibited at d 36 (p less than 0.001). Three septicemia, one corynebacteria parvum septicemia and two gram-negative septicemia despite normal neutrophil counts and oxacillin or Penicillin G plus Pefloxacin prophylaxis, occurred among the 14 patients studied. Although neutrophil functions were not more depressed in transplanted patients than in the other non transplanted patients, special attention should be paid to such patients in whom delayed immune reconstitution could increase the risk of sepsis.

UI MeSH Term Description Entries
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008297 Male Males
D009240 N-Formylmethionine Leucyl-Phenylalanine A formylated tripeptide originally isolated from bacterial filtrates that is positively chemotactic to polymorphonuclear leucocytes, and causes them to release lysosomal enzymes and become metabolically activated. F-Met-Leu-Phe,N-Formyl-Methionyl-Leucyl-Phenylalanine,Formylmet-Leu-Phe,Formylmethionyl Peptide,Formylmethionyl-Leucyl-Phenylalanine,Formylmethionylleucylphenylalanine,N-Formylated Peptide,N-formylmethionyl-leucyl-phenylalanine,fMet-Leu-Phe,F Met Leu Phe,Formylmet Leu Phe,Formylmethionyl Leucyl Phenylalanine,Leucyl-Phenylalanine, N-Formylmethionine,N Formyl Methionyl Leucyl Phenylalanine,N Formylated Peptide,N Formylmethionine Leucyl Phenylalanine,N formylmethionyl leucyl phenylalanine,Peptide, Formylmethionyl,Peptide, N-Formylated,fMet Leu Phe
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D009580 Nitroblue Tetrazolium Colorless to yellow dye that is reducible to blue or black formazan crystals by certain cells; formerly used to distinguish between nonbacterial and bacterial diseases, the latter causing neutrophils to reduce the dye; used to confirm diagnosis of chronic granulomatous disease. Nitro-BT,Nitrotetrazolium Blue,Tetrazolium Nitroblue,Blue, Nitrotetrazolium,Nitroblue, Tetrazolium,Tetrazolium, Nitroblue
D010587 Phagocytosis The engulfing and degradation of microorganisms; other cells that are dead, dying, or pathogenic; and foreign particles by phagocytic cells (PHAGOCYTES). Phagocytoses
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002448 Cell Adhesion Adherence of cells to surfaces or to other cells. Adhesion, Cell,Adhesions, Cell,Cell Adhesions
D002634 Chemotaxis, Leukocyte The movement of leukocytes in response to a chemical concentration gradient or to products formed in an immunologic reaction. Leukotaxis,Leukocyte Chemotaxis

Related Publications

A M Stoppa, and C Fossat, and D Blaise, and P Viens, and M Brandely, and C N Pourreau, and D Sainty, and G Novakovitch, and M Miquel, and I Juhan-Vague
January 1994, Progress in clinical and biological research,
A M Stoppa, and C Fossat, and D Blaise, and P Viens, and M Brandely, and C N Pourreau, and D Sainty, and G Novakovitch, and M Miquel, and I Juhan-Vague
December 1993, Seminars in oncology,
A M Stoppa, and C Fossat, and D Blaise, and P Viens, and M Brandely, and C N Pourreau, and D Sainty, and G Novakovitch, and M Miquel, and I Juhan-Vague
April 1991, Current opinion in oncology,
A M Stoppa, and C Fossat, and D Blaise, and P Viens, and M Brandely, and C N Pourreau, and D Sainty, and G Novakovitch, and M Miquel, and I Juhan-Vague
January 1993, Acta haematologica,
A M Stoppa, and C Fossat, and D Blaise, and P Viens, and M Brandely, and C N Pourreau, and D Sainty, and G Novakovitch, and M Miquel, and I Juhan-Vague
June 1991, Blood,
A M Stoppa, and C Fossat, and D Blaise, and P Viens, and M Brandely, and C N Pourreau, and D Sainty, and G Novakovitch, and M Miquel, and I Juhan-Vague
January 1993, The National medical journal of India,
A M Stoppa, and C Fossat, and D Blaise, and P Viens, and M Brandely, and C N Pourreau, and D Sainty, and G Novakovitch, and M Miquel, and I Juhan-Vague
January 1991, Schweizerische medizinische Wochenschrift. Supplementum,
A M Stoppa, and C Fossat, and D Blaise, and P Viens, and M Brandely, and C N Pourreau, and D Sainty, and G Novakovitch, and M Miquel, and I Juhan-Vague
December 1997, The cancer journal from Scientific American,
A M Stoppa, and C Fossat, and D Blaise, and P Viens, and M Brandely, and C N Pourreau, and D Sainty, and G Novakovitch, and M Miquel, and I Juhan-Vague
February 1987, Hospital practice (Office ed.),
A M Stoppa, and C Fossat, and D Blaise, and P Viens, and M Brandely, and C N Pourreau, and D Sainty, and G Novakovitch, and M Miquel, and I Juhan-Vague
January 1982, Journal of cellular physiology. Supplement,
Copied contents to your clipboard!